Wei Neng Chen

20130096694, Apr 18, 2013

Jun 21, 2012

13/529833

Ryan J. Caldwell - Long Grove IL, US
Andrew H. Hansen - Apple Valley MN, US
Sean M. Wood - Gardena CA, US
Wei Chen - Glenview IL, US
Regan A. Radcliffe - Sunnyvale CA, US
Kevin A. Yngve - Evanston IL, US
Bennett E. Kuhar - Concord Twp. OH, US
Andrew J. Nelson - Chicago IL, US
Eric Nickel - Brooklyn Park MN, US

NORTHWESTERN UNIVERSITY - Evanston IL

A61F 2/80

623 34

Pump systems for use in suspension of a prosthetic device from a residual limb and methods of suspending a prosthetic device from a residual limb are disclosed. The pump systems include a mechanically activated pump having a first compression member coupled to a second compression member, a compressible bladder disposed between the first and second compression members, and coupling elements that engage and couple together the first and second compression members. The mechanically activated pump may be connected with an electrically activated pump within a fluid circuit of a hybrid pump system to provide vacuum engagement between a prosthetic device and a residual limb.

60432713, Mar 28, 2000

Aug 2, 1995

8/510213

Michael T. Flavin - Darien IL
Ze-Qi Xu - Naperville IL
John D. Rizzo - Downers Grove IL
Alla Kucherenko - Naperville IL
Albert Khilevich - Glenview IL
Abram Kivovich Sheinkman - Naperville IL
Vilayphone Vilaychack - Elgin IL
Lin Lin - Chicago IL
Wei Chen - Naperville IL
William A. Boulanger - Schenectady NY

Sarawak MediChem Pharmaceuticals, Inc. - Lemont IL

A61K 3135
C07D40700

514453

A method of preparing (. +-. )-calanolide A, 1, a potent HIV reverse transcriptase inhibitor, from chromene 4 is provided. Useful intermediates for preparing (. +-. )-calanolide A and its derivatives are also provided. According to the disclosed method, chromene 4 intermediate was reacted with acetaldehyde diethyl acetal or paraldehyde in the presence of an acid catalyst with heating, or a two-step reaction including an aldol reaction with acetaldehyde and cyclization either under acidic conditions or neutral Mitsunobu conditions, to produce chromanone 7. Reduction of chromanone 7 with sodium borohydride, in the presence of cerium trichloride, produced (. +-. )-calanolide A. A method for resolving (. +-. )-calanolide A into its optically active forms by a chiral HPLC system or by enzymatic acylation and hydrolysis is also disclosed. Finally, a method for treating or preventing a viral infections using (. +-.

58693246, Feb 9, 1999

Sep 8, 1997

8/933619

Michael T. Flavin - Darien IL
Ze-Qi Xu - Naperville IL
John D. Rizzo - Downers Grove IL
Alla Kucherenko - Naperville IL
Albert Khilevich - Glenview IL
Abram Kivovich Sheinkman - Naperville IL
Vilayphone Vilaychack - Elgin IL
Lin Lin - Chicago IL
Wei Chen - Naperville IL
William A. Boulanger - Schenectady NY

Sarawak MediChem Pharmaceuticals, Inc. - Lemont IL

C12P 4100

435280

A method of preparing (. +-. )-calanolide A, 1, a potent HIV reverse transcriptase inhibitor, from chromene 4 is provided. Useful intermediates for preparing (. +-. )-calanolide A and its derivatives are also provided. According to the disclosed method, chromene 4 intermediate was reacted with acetaldehyde diethyl acetal or paraldehyde in the presence of an acid catalyst with heating, or a two-step reaction including an aldol reaction with acetaldehyde and cyclization either under acidic conditions or neutral Mitsunobu conditions, to produce chromanone 7. Reduction of chromanone 7 with sodium borohydride, in the presence of cerium trichloride, produced (. +-. )-calanolide A. A method for resolving (. +-. )-calanolide A into its optically active forms by a chiral HPLC system or by enzymatic acylation and hydrolysis is also disclosed. Finally, a method for treating or preventing viral infections using (. +-.

20190247423, Aug 15, 2019

Sep 29, 2017

16/338330

- Chicago IL, US
Olga Y. Zaborina - Brookfield IL, US
Jun Mao - Chicago IL, US
Wei Chen - Chicago IL, US

A61K 31/77
C08G 65/335
C08G 81/00
A61P 31/04
A61P 1/00

The disclosure provides products and methods of treating diseases and disorders involving microbial pathogens, such as intestinal microbial pathogens, e.g., , by administering an effective amount of a phosphorylated polyethylene glycol compound of defined structural organization. Those diseases and disorders characterized by an epithelium attacked by a microbial pathogen are contemplated, including gastrointestinal infections and inflammation, e.g., treatment of intestinal or esophageal anastomosis or treatment or suppression of anastomotic leakage.